A novel nintedanib ophthalmic nanosuspension (AG | 化學工廠資訊網
由TNguyen著作·2019—AG-86893(0.1–1%)wasdevelopedandtestedtoassessitsefficacyfollowingTIDdosingfor7daysafterinductionofNV.
Abstract
Purpose : Cytokines such as epidermal growth factor, fibroblast growth factor-2, nerve growth factor, platelet derived growth factor, transforming growth factor-β and vascular endothelial growth factor are thought to play a role in the formation of pterygium. We hypothesized that inhibition of one or more of these cytokines by tyrosine kinase inhibitors (TKIs) could be used to treat pterygium. We tested our hypothesis using a rabbit corneal neovascularization model.
Methods : Microsuspensions (0.3%) of three TKIs (nintedanib, axitinib, and sorafenib) were tested in a rabbit corneal neovascularization (NV) model to determine their ability to inhibit NV following three times daily (TID) ocular dosing for 14 days (N=6 eyes/group). AG-86893 (0.1 – 1%) was developed and tested to assess its efficacy following TID dosing for 7 days after...
A novel nintedanib ophthalmic nanosuspension (AG | 化學工廠資訊網
A Study of the Response to AG | 化學工廠資訊網
A Study of the Response to AG | 化學工廠資訊網
AffaMed Therapeutics 和Allgenesis Biotherapeutics 宣布达成 ... | 化學工廠資訊網
AG 86893 | 化學工廠資訊網
Clinical Trial on Pterygium: 0.1% AG | 化學工廠資訊網
Could Eye Drops Fix a Pterygium? | 化學工廠資訊網
Pterygium Trial in Australia (0.1% AG | 化學工廠資訊網
【臺北市】新源生物科技股份有限公司
臺北市化工廠有哪些?本篇為大家整理位於松山區八德路4段760號7樓之1的「新源生物科技股份有限公司」相關資訊,用列表的方式...